Zim Laboratories Limited (ZIMLAB) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.036x

Based on the latest financial reports, Zim Laboratories Limited (ZIMLAB) has a cash flow conversion efficiency ratio of 0.036x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs81.71 Million ≈ $883.66K USD) by net assets (Rs2.26 Billion ≈ $24.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Zim Laboratories Limited balance sheet independence to measure how much of total assets are equity-financed.

Zim Laboratories Limited - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Zim Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Zim Laboratories Limited to evaluate the quality of earnings relative to operating cash generation.

Zim Laboratories Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Zim Laboratories Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
EISO Enterprise Co Ltd
TWO:5291
0.010x
Pancontinental Energy NL
AU:PCL
-0.064x
Mesa Air Group Inc
NASDAQ:MESA
0.054x
Mastermyne Group Ltd
AU:MYE
0.071x
Campina Ice Cream Industry Tbk PT
JK:CAMP
0.086x
Shinwon
KO:009270
0.067x
Chemfab Alkalis Limited
NSE:CHEMFAB
0.030x
AmFIRST Real Estate Investment Trust
KLSE:5120
0.013x

Annual Cash Flow Conversion Efficiency for Zim Laboratories Limited (2013–2025)

The table below shows the annual cash flow conversion efficiency of Zim Laboratories Limited from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see ZIMLAB market cap.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs2.52 Billion
≈ $27.28 Million
Rs411.55 Million
≈ $4.45 Million
0.163x +139.30%
2024-03-31 Rs2.39 Billion
≈ $25.82 Million
Rs162.78 Million
≈ $1.76 Million
0.068x -63.59%
2023-03-31 Rs2.00 Billion
≈ $21.67 Million
Rs375.19 Million
≈ $4.06 Million
0.187x -33.13%
2022-03-31 Rs1.76 Billion
≈ $19.00 Million
Rs492.06 Million
≈ $5.32 Million
0.280x +41.33%
2021-03-31 Rs1.61 Billion
≈ $17.38 Million
Rs318.51 Million
≈ $3.44 Million
0.198x +39.07%
2020-03-31 Rs1.54 Billion
≈ $16.64 Million
Rs219.15 Million
≈ $2.37 Million
0.142x -38.25%
2019-03-31 Rs1.51 Billion
≈ $16.34 Million
Rs348.65 Million
≈ $3.77 Million
0.231x -13.92%
2018-03-31 Rs1.37 Billion
≈ $14.77 Million
Rs366.13 Million
≈ $3.96 Million
0.268x -1.11%
2017-03-31 Rs1.18 Billion
≈ $12.80 Million
Rs320.71 Million
≈ $3.47 Million
0.271x +21.46%
2016-03-31 Rs983.37 Million
≈ $10.63 Million
Rs219.43 Million
≈ $2.37 Million
0.223x +276.37%
2015-03-31 Rs942.10 Million
≈ $10.19 Million
Rs55.85 Million
≈ $604.04K
0.059x +105.44%
2014-03-31 Rs1.16 Billion
≈ $12.55 Million
Rs33.48 Million
≈ $362.11K
0.029x +113.30%
2013-03-31 Rs1.07 Billion
≈ $11.55 Million
Rs-231.81 Million
≈ $-2.51 Million
-0.217x --

About Zim Laboratories Limited

NSE:ZIMLAB India Drug Manufacturers - Specialty & Generic
Market Cap
$58.62 Million
Rs5.42 Billion INR
Market Cap Rank
#21260 Global
#1171 in India
Share Price
Rs111.23
Change (1 day)
-1.56%
52-Week Range
Rs60.26 - Rs127.87
All Time High
Rs149.00
About

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers the… Read more